Drug General Information (ID: DDIBWY32CI)
Drug Name			Alemtuzumab		Drug Info		Lutetium Lu 177 dotatate		Drug Info
Drug Type		Monoclonal antibody				Small molecule
Therapeutic Class		Antineoplastics				Therapeutic Radiopharmaceuticals

Mechanism of Alemtuzumab-Lutetium Lu 177 dotatate Interaction (Severity Level: Moderate)
Additive myelosuppressive effects Click to Show/Hide Mechanism Graph
Drug Name		Alemtuzumab				Lutetium Lu 177 dotatate
Mechanism		Myelosuppressive effects				Myelosuppressive effects
Key Mechanism Factor 1
		Factor Name		Myelosuppressive effects
		Factor Description		Myelosuppression, also known as bone marrow suppression, is a decrease in bone marrow activity that leads to a decrease in the production of blood cells. Some blood cell disorders include: erythrocytopenia (anemia), leukopenia (neutropenia), and thrombocytopenia (thrombocytopenia).
Mechanism Description		Additive myelosuppressive effects by the combination of Alemtuzumab and Lutetium Lu 177 dotatate

Recommended Action
Management		Caution is advised if alemtuzumab must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. The manufacturer recommends that single doses of alemtuzumab not exceed 30 mg and cumulative weekly doses not exceed 90 mg, since higher dosages are associated with an increased incidence of pancytopenia. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy.

References
1	Product Information. Campath (alemtuzumab) Berlex, Richmond, CA.